COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia

Schizophr Res. 2007 Sep;95(1-3):253-5. doi: 10.1016/j.schres.2007.06.014. Epub 2007 Jul 17.

Authors

Alessandro Bertolino, Grazia Caforio, Giuseppe Blasi, Antonio Rampino, Marcello Nardini, Daniel R Weinberger, Bruno Dallapiccola, Lorenzo Sinibaldi, Sophia Douzgou

PMID: 17644310
DOI: 10.1016/j.schres.2007.06.014

No abstract available

Publication types

Letter

MeSH terms

Antipsychotic Agents / therapeutic use*
Benzodiazepines / therapeutic use*
Catechol O-Methyltransferase / genetics*
Genotype
Humans
Methionine / genetics
Olanzapine
Pharmacogenetics
Polymorphism, Genetic / genetics*
Polymorphism, Single Nucleotide
Psychiatric Status Rating Scales / statistics & numerical data*
Schizophrenia / diagnosis
Schizophrenia / genetics*
Schizophrenic Psychology*
Treatment Outcome
Valine / genetics

Substances

Antipsychotic Agents
Benzodiazepines
Methionine
Catechol O-Methyltransferase
Valine
Olanzapine